市場調査レポート

商品コード

1593505

プロトンポンプ阻害薬の市場規模・シェア・成長分析 (薬剤の種類別、投与経路別、剤形別、処方薬別、適応症別、地域別)：産業予測 (2024～2031年)

Proton Pump Inhibitors Market Size, Share, Growth Analysis, By Drug Type (Esomeprazole, Omeprazole), By Route of Administration (Oral, Injectable), By Dosage Form, By Prescription, By Indication, By Region - Industry Forecast 2024-2031

出版日: 2024年11月09日
発行: SkyQuest
ページ情報: 英文 196 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 763,518円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 893,172円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,022,826円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
目次

概要

サンプル依頼リストに入れる

プロトンポンプ阻害薬の世界市場規模は、2022年に約46億5,000万米ドルと評価され、2023年の49億米ドルから上昇し、予測期間 (2024～2031年) のCAGRは5.2%で、2031年には73億5,000万米ドルに達すると予測されています。

プロトンポンプ阻害薬 (PPI) は製薬業界において重要なセグメントであり、主に消化性潰瘍、ゾリンジャー・エリソン症候群、胃食道逆流症 (GERD) などの消化器疾患に対応しています。これらの薬剤は、胃の内壁にあるプロトンポンプを阻害することで機能し、胃酸レベルを効果的に低下させます。酸に関連する疾患の世界的な急増は、OTC (市販医薬品) のPPI需要を促進しており、この傾向は、薬剤製剤の継続的な進歩とともに、このような治療をしばしば必要とする高齢化によってさらに強まっています。しかし市場は、特許切れによるジェネリック医薬品との競合激化や、規制上のハードル、PPIの長期使用に伴う長期的な副作用への懸念といった課題に直面しています。こうした障害にもかかわらず、特に製剤の革新、デジタルヘルス技術の統合、セルフメディケーションに対する消費者の志向の高まりによって、市場には機会があふれています。これらのダイナミクスは、消費者の嗜好や医療提供システムの進化に適応しながら、PPIが高まる健康課題に対処する上で大きな可能性を秘めていることを示しています。全体として、市場が一定の課題を克服している一方で、効果的な消化管治療に対する継続的な需要が、市場の回復力と将来の成長への期待を裏付けています。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ
中東・アフリカ (MEA)
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情勢

上位5社の比較
主要企業の市場ポジショニング (2023年)
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア (2023年)

主要企業プロファイル

AstraZeneca (英国)
Pfizer Inc. (米国)
Takeda Pharmaceutical Company (日本)
Bayer AG (ドイツ)
GlaxoSmithKline plc (英国)
Dr. Reddy's Laboratories Ltd. (インド)
Teva Pharmaceutical Industries Ltd. (イスラエル)
Sun Pharmaceutical Industries Ltd. (インド)
Sanofi S.A. (フランス)
Pharma Dynamics (Pty) Ltd. (南アフリカ)
AbbVie Inc. (米国)
Lupin Limited (インド)
Eisai Co., Ltd. (日本)
Cadila Healthcare Ltd. (Zydus Cadila) (インド)
Cipla Ltd. (インド)
Merck & Co., Inc. (米国)
F. Hoffmann-La Roche Ltd. (スイス)
Torrent Pharmaceuticals Ltd. (インド)
RedHill Biopharma Ltd. (イスラエル)
Sumitomo Dainippon Pharma Co., Ltd. (日本)

Product Code: SQMIG35B2218

Global Proton Pump Inhibitors Market size was valued at around USD 4.65 billion in 2022 and is expected to rise from USD 4.90 billion in 2023 to reach a value of USD 7.35 billion by 2031, at a CAGR of 5.2% over the forecast period (2024-2031).

Proton pump inhibitors (PPIs) represent a significant segment within the pharmaceutical industry, primarily addressing gastrointestinal disorders like peptic ulcers, Zollinger-Ellison syndrome, and gastroesophageal reflux disease (GERD). These medications function by inhibiting proton pumps in the stomach lining, effectively reducing stomach acid levels. The global surge in acid-related conditions is propelling the demand for over-the-counter (OTC) PPIs, a trend further intensified by an aging population that often requires such treatments, alongside continuous advancements in drug formulations. However, the market faces challenges from the expiration of patents, which has led to heightened competition from generic alternatives, as well as regulatory hurdles and concerns regarding the long-term side effects associated with prolonged PPI usage. Despite these obstacles, opportunities abound in the market, particularly through innovations in drug formulations, the integration of digital health technologies, and a growing consumer inclination towards self-medication. These dynamics indicate a robust potential for PPIs in addressing rising health challenges while adapting to the evolving landscape of consumer preferences and healthcare delivery systems. Overall, while the market navigates certain challenges, the continual demand for effective gastrointestinal treatments underscores its resilience and promise for future growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Proton Pump Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Proton Pump Inhibitors Market Segmental Analysis

Global Proton Pump Inhibitors Market is segmented by Drug Type, Route of Administration, Dosage Form, Prescription, Indication, Distribution Channel and region. Based on Drug Type, the market is segmented into Esomeprazole, Omeprazole, Dexlansoprazole, Pantoprazole, Rabeprazole, Lansoprazole, and Others. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Dosage Form, the market is segmented into Tablet, Capsules, Injection, and Others. Based on Prescription, the market is segmented into Branded, and Generics. Based on Indication, the market is segmented into Gastroesophageal Reflux Disease, Heartburn, Peptic ulcers, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Proton Pump Inhibitors Market

The Global Proton Pump Inhibitors (PPIs) market is being significantly driven by the emergence of innovative formulations and delivery systems that enhance the therapeutic efficacy and safety profiles of these medications. The introduction of extended-release PPIs allows for improved patient compliance and more effective management of acid-related disorders. Furthermore, the development of combination therapies, where PPIs are synergistically used with other therapeutic agents, caters to the treatment of complex gastrointestinal conditions, thereby expanding their clinical applicability. This modernization in drug development not only meets evolving patient needs but also fosters a competitive landscape, propelling the overall market growth of PPIs.

Restraints in the Global Proton Pump Inhibitors Market

The Global Proton Pump Inhibitors (PPIs) market faces significant restraints due to the adverse health effects associated with prolonged use of these medications. Risks such as increased chances of bone fractures, kidney disease, and deficiencies in crucial vitamins like magnesium and B12 are prompting healthcare professionals to exercise greater caution in prescribing PPIs. This heightened vigilance may lead to reduced prescription rates, ultimately suppressing market growth. Additionally, the potential for long-term PPI use to contribute to Clostridium difficile infections poses further challenges, complicating treatment protocols and negatively impacting patient outcomes, thereby affecting the overall demand for these products in the healthcare industry.

Market Trends of the Global Proton Pump Inhibitors Market

The Global Proton Pump Inhibitors (PPIs) market is experiencing a notable trend towards the introduction of alternatives and innovative formulations designed to improve treatment outcomes while minimizing side effects. Researchers are actively developing novel delivery systems, including combination therapies and delayed-release formulations to enhance efficacy. Concurrently, there's a burgeoning interest in alternative therapies such as prokinetic agents and H2-receptor antagonists, alongside dietary modifications to manage acid-related disorders more effectively. This shift not only reflects the growing demand for personalized medicine but also addresses concerns regarding long-term PPI use, ultimately reshaping the landscape of acid suppression treatments.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Innovation Matrix
Top Investment Pockets
Ecosystem of the Market
Value Chain Analysis
Technology Analysis
Regulatory Analysis
Clinical trials Analysis
Customer & Buying Criteria Analysis

Proton Pump Inhibitors Market, By Drug Type

Market Overview
Esomeprazole
Omeprazole
Dexlansoprazole
Pantoprazole
Rabeprazole
Lansoprazole
Others

Proton Pump Inhibitors Market, By Route of Administration

Market Overview
Oral
Injectable

Proton Pump Inhibitors Market, By Dosage Form

Market Overview
Tablet
Capsules
Injection
Others

Proton Pump Inhibitors Market, By Prescription

Market Overview
Branded
Generics

Proton Pump Inhibitors Market, By Indication

Market Overview
Gastroesophageal Reflux Disease
Heartburn
Peptic ulcers
Others

Proton Pump Inhibitors Market, By Distribution Channel

Market Overview
Hospital Pharmacies
Retail Pharmacies
Drug Stores and Clinics
Others

Proton Pump Inhibitors Market, by region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pharma Dynamics (Pty) Ltd. (South Africa)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cadila Healthcare Ltd. (Zydus Cadila) (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Torrent Pharmaceuticals Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
RedHill Biopharma Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sumitomo Dainippon Pharma Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

プロトンポンプ阻害薬の市場規模・シェア・成長分析 (薬剤の種類別、投与経路別、剤形別、処方薬別、適応症別、地域別)：産業予測 (2024～2031年)

Proton Pump Inhibitors Market Size, Share, Growth Analysis, By Drug Type (Esomeprazole, Omeprazole), By Route of Administration (Oral, Injectable), By Dosage Form, By Prescription, By Indication, By Region - Industry Forecast 2024-2031

目次

イントロダクション

分析手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

プロトンポンプ阻害薬市場：薬剤の種類別

プロトンポンプ阻害薬市場：投与経路別

プロトンポンプ阻害薬市場：剤形別

プロトンポンプ阻害薬市場：処方薬別

プロトンポンプ阻害薬市場：適応症別

プロトンポンプ阻害薬市場：流通チャネル別

プロトンポンプ阻害薬市場：地域別